

Circuit Mechanisms of Action of Classic Psychedelics and MDMA

Katrin Preller, PhD



NAS, March 29 2022

COI

KHP is currently an employee of Boehringer Ingelheim GmbH & Co. KG This position is not related to the content of this talk.

Psychoactive Substances

Psilocybin



preferential **5-HT2A** and **5-HT1A** agonist

DMT



preferential 5-HT2A agonist

LSD



stimulates **serotonin** and **dopamine** receptors

MDMA



serotonin, **norepinephrine** and **dopamine** releaser


Psychedelics Change the Activity of Neurons






Preller et al. 2018


From Neurons to Interactions with the Environment




From Neurons to Interactions with the Environment




The Thalamic Filter Model



Thalamic Seed-Based Connectivity




Thalamic Connectivity under LSD




red: increased effective connectivity blue: decreased effective connectivity

What about the Cortex?




Changes in GBC are similar under LSD and Psilocybin




Preller et al., 2020; Preller at al., 2018


Time-dependent Effects of Psilocybin




LSD-incuded Changes correlate with HTR2A Gene Expression



Baseline Connectivity Correlates with Magnitude of Psilocybin Effects




Dysbalance between Sensory Processing and Integration




Vollenweider & Preller, 2020, NRN

Circuit-Level Changes under MDMA




Lasting effects of single doses




Post-acute Circuit Changes (24h)


Ayahuasca: healthy participants



Psilocybin: depressed patients




Long-term Circuit Changes: No consistent pattern



Conclusions

- Acute changes in thalamic gating and network (dis-) integration
- Changes in functional connectivity align with 5-HT2A receptor distribution
- Similar effects across psychedelics, not MDMA
- Inconsistent results on long-term changes so far





Knowledge Gaps

- How do cuircuit-level changes contribute to clinical efficacy?
- Trans-diagnostic mechanism is unclear
- Inter-individual variability is unclear
- Dose-response studies are missing
- Cross-pharmacology comparisons are needed to understand specificity of (network) effects
 - ► Understanding the mechanism of action is essential for optimizing the therapeutic approach











Thank you!

Psychiatrische Universitätsklinik Zürich:

Franz Vollenweider

Erich Seifritz

Patricia Dürler

Philipp Stämpfli

Marcus Herdener

Thomas Pokorny

Sara Romer

Nathalie Rieser

Flora Moujaes

University College London:

Karl Friston

Peter Zeidman

Adeel Razi

Yale University:

Alan Anticevic

John Murray

John Krystal

Joshua Burt

Ji Lisa Jie

MPI of Psychiatry Munich:

Leonhard Schilbach